Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > WSJ Article - courtesy MSN.COM

<< Previous

Bullboard Posts

Next >>

Comment by BlueJays9293on Jul 10, 2024 11:05pm

196 Views

Post# 36127637

RE:RE:RE:RE:WSJ Article - courtesy MSN.COM

As it stands today, Carlyle Group is probably committing to $4B for $300MM in profits, or in other words, they are plopping down each Billion for the rights to $75mm in profits.

So the question and investment thesis becomes,

why wouldn't they plop down $2B to gain the rights on an additional $300mm in profits,

or in other words, each billion for the rights to $150mm in profits?

Doesn't seem absurd to me.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features